CHINARES PHARMA (03320) Subsidiary Completes Issuance of RMB1.1 Billion Corporate Bonds

Stock News

2025/11/18

CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate bonds in China. The second tranche, with a total principal of RMB1.1 billion, carries a 3-year term and an annual coupon rate of 1.78%. The net proceeds from the bond issuance will be allocated for productive expenditures, including debt repayment, working capital replenishment, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1157451480"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157451480\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157451480?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157451480","market":"other","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Subsidiary Completes Issuance of RMB1.1 Billion Corporate Bonds","media":"Stock News","content":"<p>CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate bonds in China. The second tranche, with a total principal of RMB1.1 billion, carries a 3-year term and an annual coupon rate of 1.78%. The net proceeds from the bond issuance will be allocated for productive expenditures, including debt repayment, working capital replenishment, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Subsidiary Completes Issuance of RMB1.1 Billion Corporate Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Subsidiary Completes Issuance of RMB1.1 Billion Corporate Bonds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-18 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate bonds in China. The second tranche, with a total principal of RMB1.1 billion, carries a 3-year term and an annual coupon rate of 1.78%. The net proceeds from the bond issuance will be allocated for productive expenditures, including debt repayment, working capital replenishment, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"","article_id":"1157451480","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157451480","pubTimestamp":1763465178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1570":"华润系","03320":"华润医药","BK1191":"制药"},"translate_title":"中国医药(03320)附属公司完成人民币11亿元公司债券发行","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate bonds in China. The second tranche, with a total principal of RMB1.1 billion, carries a 3-year term and an annual coupon rate of 1.78%. The net proceeds from the bond issuance will be allocated for productive expenditures, including debt repayment, working capital replenishment, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}